Commit calls for Nykode CSO Mikkel Wandahl Pedersen

Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen (pictured, above) as chief scientific officer (CSO).

Dr Pedersen is a seasoned R&D executive and scientific leader with more than two decades of experience in immuno-oncology and autoimmune disease drug discovery and development.

Most recently, he served as the CSO of Oslo-based Nykode Therapeutics (NYKD. OL), where he created and executed a new research strategy, scaled the research organization to support an expanding pipeline, and spearheaded key collaborations with external pharmaceutical partners.